Isotechnika Inc. completes critical study
Isotechnika Inc. announced the results from the rat carcinogenicity study for its lead immunosuppressive drug, ISA247. ISA247 did not exhibit any carcinogenicity up to the highest doses tested in male and female rats over a two year period.
Carcinogenicity studies are required by the United States Food and Drug Administration (FDA) and other Regulatory Authorities and are a critical part of the package submitted for marketing approval. Carcinogenicity studies are performed by administering a range of doses of a drug, including a dose considerably higher than the anticipated clinical dose for a period of two years. This timeframe is equivalent to administering the drug over a lifetime in humans.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Illumina To Conduct Large-Scale Genotyping For Uk-Based Research Groups Studying Molecular Basis Of Prostate Cancer
Cipher reaches agreement to dismiss patent litigation in United States for CIP-Fenofibrate
Genomatix met cash-flow break-even in 2003
Breakthrough at Ark opens way to reduce side-effects and increase efficacy of anti-cancer therapies - Unique DNA-based targeting technology Scavidin halts tumour progression with one-tenth of conventional chemotherapy dose
BioFocus and Almac collaborate to offer fluorescent lifetime assays
Genentech to set up Singapore's first Microbial-Based Biopharmaceutical Manufacturing Facility - Fourth Biologics Facility in Less Than 2 Years Helps Establish Singapore as a Serious Player in Biologics Manufacturing
Arakis completes Phase I trials of AD 337 in fibromyalgia syndrome
ABRAXANE meets primary endpoint in phase 3 trial for advanced non-small cell lung cancer
Oncolytics Biotech Inc. has been granted patent for extracting virus from cell culture
Researchers identify genes linked to chemoresistance
